Bacterium

Thermodynamic Integration Combined with Molecular Dynamic Simulations to Explore the Cross‐Resistance Mechanism of Isoniazid and Ethionamide

13 days ago   |   By Wiley

Abstract
Tuberculosis is an ancient disease of mankind, and its causative bacterium is Mycobacterium tuberculosis. Isoniazid is one of the most effective first-line anti-tuberculosis drugs. As prodrugs, it and its derivative ethionamide act on enoyl-acyl carrier protein reductase after being oxidized in bacteria, and kill the bacteria by inhibiting the formation of Mycobacterium tuberculosis cell walls. However, the S94A mutation of InhA causes Mycobacterium tuberculosis to develop cross-resistance to isoniazid and ethionamide. This work is dedicated to studying the cross-resistance...
Read more ...

 


Search by Tags

   Bacterium      Drug      Energy      Protein      Drugs      RESEARCH ARTICLE  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Biological modification of pentosans in wheat B starch wastewater and...

Petrochemical resources are becoming increasingly scarce, and petroleum-based plastic materials adversely impact the environment. Thus, replacement of petroleum-based materials... Read more ...

Research Associate - Molecular Cellular Biologist - Activx - La Jolla, CA

The successful candidate will work with senior scientists to design and execute experiments to validate drug targets and to characterize compounds that modulate... $48,000... Read more ...

N-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi...

SAN DIEGO-- ASO-n-Lorem and Alnylam Partner to Expand Technology Access to RNAi Read more ...

The amyloid concentric β‐barrel hypothesis: Models of amyloid beta 42...

Abstract Amyloid beta peptides are a major contributor to Alzheimers disease. They occur in differing lengths, each of which forms a multitude of assembly types. The most toxic... Read more ...

Crystal Structure of a Human MUC16 SEA Domain Reveals Insight Into the...

Abstract MUC16 is a membrane bound glycoprotein involved in the progression and metastasis of pancreatic and ovarian cancer. The protein is shed into the serum and the... Read more ...

Senior Mechanical Design Engineer - NanoCellect Biomedical, Inc. - San Diego, CA

Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, and...From NanoCellect... Read more ...

Kurin, Inc. Announces Agreement with AllSpire Health GPO to Impact...

SAN DIEGO--Kurin, Inc. announced the signing of a sole-source, three-year agreement with AllSpire Health GPO for Kurin blood culture collection sets. Read more ...

PhenoVista Biosciences Raises Growth Capital From BroadOak Capital Partners

SAN DIEGO--PhenoVista Biosciences announces investment from BroadOak Capital Partners. Read more ...

Advances in 3D printing of composite scaffolds for the repairment of bone...

Abstract The conventional methods of using autografts and allografts for repairing defects in bone, the osteochondral bone and the cartilage tissue have many disadvantages... Read more ...

Ionis' partner to evaluate tominersen for Huntington's disease in new Phase...

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 18, 2022 /PRNewswire/ - Ionis Pharmaceuticals, Inc. announced that its partner, Roche, is designing a new Phase 2 trial to evaluate... Read more ...